Sensus Healthcare (SRTS)

The company is best known for superficial radiation therapy, a form of low-energy radiation designed to treat lesions near the surface of the skin. Sensus markets systems including the SRT-100 and SRT-100 Vision, with the latter incorporating imaging capabilities that help clinicians visualise and manage treatment areas. These products are intended to give physicians a non-surgical option for selected patients, including those who may not be ideal candidates for surgery because of age, lesion location, medical condition, or cosmetic considerations.

Sensus also provides service and support programmes, including its Sentinel service offering, which are important for maintaining device performance, customer relationships, and recurring revenue opportunities. The company’s customer base is concentrated largely in the United States, where dermatology practices, radiation oncologists, and other clinical providers evaluate its systems as part of skin cancer treatment workflows.

As a small medical device company, Sensus is influenced by capital equipment purchasing cycles, procedure adoption, reimbursement, clinical acceptance, and competition from surgical and other treatment methods. Its investment profile is tied to the broader demand for non-invasive or minimally invasive skin cancer therapies and the ability of its technology to demonstrate practical value in physician offices and outpatient care settings.